New and Approved: Review of Radiopharmaceutical Therapies

Course overview

UAN: 0018-0000-19-303-H01-P & T RELEASE: 08/29/2019 EXPIRE: 08/29/2022 CREDITS: 2.0 LEARNING OBJECTIVES: 1. Review general information regarding LUTATHERA (lutetium Lu 177 dotatate) 2. Describe the fundamentals of the theragnostic approach 3. Summarize the steps in the synthesis and dispensing of Lutathera 4. Describe quality control methods and considerations when producing Lutathera 5. Identify appropriate steps in the packaging and preparation of Lutathera 6. Review the approved LUTATHERA dosing regimen and administration procedure 7. Review available support options for LUTATHERA users 8. Explain the clinical indication and use of 131I-Iobenguane (Azedra). 9. To understand the basic biology of 131I-Iobenguane and its possible side effects. 10 To review clinical trial findings. 11. To know pertinent guidelines in dispensing and administering 131I-Iobenguane. NOTE: An annual subscription for Purdue's nuclear pharmacy re-certification program provides access to both the continuing education component of the program and the "Radiopharmacy Portal" a reference resource for practitioners. Subscriptions to the continuing educational offerings, which have been accredited through ACPE and BPS, can be purchased for an annual fee of $195 for nuclear pharmacists and $95 for nuclear pharmacy technicians.